Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
ID | Components | Size |
EP166-C01 | High-bind Plate | 1plate |
EP166-C02 | Human CD73 | 1μg |
EP166-C03 | AMP | 500μL |
EP166-C04 | AMP-CP(CD73 Inhibitor) | 30μL |
EP166-C05 | 1xDilution Buffer | 50mL |
EP166-C06 | Malachite Green Reagent A | 2mL |
EP166-C07 | Malachite Green Reagent B | 2mL |
The opened kit should be stored per components table. The shelf life is 30 days from the date of opening.
INHIBITION OF CD73: AMP BINDING BY AMP-CP
Serial dilutions of AMP-CP (1:1 serial dilution, from 500μm/L to 0.244140625μm/L) was added into CD73: AMP binding reactions. The assay was performed according to the protocol described below. Background was subtracted from data points prior to log transformation and curve fitting (QC tested).
Emerging VoCs, Omicron, Delta, Beta, Alpha mutants and so on, including RBD, S trimer, S1, NTD, NP, etc. These mutants are of high purity and bioactivity and can be used to evaluate the efficacy of the antibodies and vaccination.
ACROBiosystems developed a series of GMP grade cytokines under the GMP grade quality management system. Those products are all suitable for T/NK cell generation, activation, and proliferation in cell therapy research.
50+ targets designed for CAR detection, including PE/FITC/biotin labeled proteins. The key reagents for CD19 and BCMA were FDA DMF filed which can support your IND, NDA and BLA process.
GMP grade cytokines, reagents for cell activation, gene edition, DNA/RNA removal, etc. Particularly focus on product design, quality control and solution-based support to link each phase of your cell and gene therapy journey.
Full length multi-pass TPs with stabilized structure and high bioactivity for immunization, antibody screening, cell based assay and CAR detection, including hot CD20, Claudin 18.2, CD133, GPRC5D,CCR8, CCR5, etc.
CD3 proteins and a collection of for bispecific antibody development which are of high specificity and bioactivities and suitable for immunization, antibody screening.
A series of immune checkpoints including classic co-inhibitory and co-stimulatory receptors. The comprehensive catalog contains 100+ targets with various species and tags, and the high-quality proteins are in good batch-to-batch consistency.
To meet the needs of ADCs development, ACROBiosystems can provide: A variety of high-quality target proteins; MMPs/Cathepsin/uPA for cleavable linker; Anti-payload antibodies & anti-idiotypic antibodies for immunogenicity and PK analysis; SPR/BLI analytical and ADA development service.
Comprehensive collection of Fc receptor proteins, including their common variants, which can help expedite your antibody development.
The MABSOL biotinylated protein collection includes more than a hundred commonly studied drug targets and biomarker proteins.
Comprehensive cytokines including IL families, growth factors, chemokines, TNFs, etc. These products are HEK293 expressed and nearly in authentic structure, high purity and bioactivity, cell based assay/SPR/BLI verified.
To support preclinical/clinical immunogenicity and PK analysis, ACROBiosystems has developed a series of high-affinity anti-idiotypic antibodies. Our pipeline covers five hot targets including adalimum*b, rituxim*b, cetuxim*b, trastuzum*b, and bevacizum*b.
English Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
---|
English Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
Anti-CD73 monoclonal antibody (Bristol-Myers Squibb) | Phase 1 Clinical | Neoplasms | Details | ||
BR-101 | BR101; BR-101 | Phase 1 Clinical | BioRay Pharmaceutical Co Ltd | Solid tumours | Details |
BMS-986179 | BMS-986179 | Bristol-Myers Squibb Company | Details | ||
LY-3475070 | LY-3475070 | Eli Lilly And Company | Details | ||
PM-1015 | PM1015; PM-1015 | Phase 1 Clinical | Biotheus Inc | Solid tumours | Details |
ORIC533 | ORIC-533 | Phase 1 Clinical | Oric Pharmaceuticals Inc | Multiple Myeloma; Neoplasm Metastasis | Details |
IPH-5301 | IPH-5301 | Phase 1 Clinical | Innate Pharma | Solid tumours; Ovarian Neoplasms; Esophageal Neoplasms; Stomach Neoplasms; Pancreatic Neoplasms; Neoplasms; Breast Neoplasms; Lung Neoplasms; Endometrial Neoplasms; Neoplasm Metastasis | Details |
IBI-325 | IBI-325 | Phase 1 Clinical | Innovent Biologics(Suzhou) Co Ltd | Solid tumours | Details |
Mupadolimab | CPI-006 | Phase 2 Clinical | Corvus | Coronavirus Disease 2019 (COVID-19); Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung; Lymphoma, Non-Hodgkin; Endometrial Neoplasms; Colorectal Neoplasms; Prostatic Neoplasms; Sarcoma; Urinary Bladder Neoplasms; Head and Neck Neoplasms; Pancreatic Neoplasms; Triple Negative Breast Neoplasms; Papillomavirus Infections; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Renal Cell; Solid tumours; Ovarian Neoplasms | Details |
JAB-BX102 | JAB-BX102 | Phase 2 Clinical | Jacobio Pharmaceuticals Co Ltd | Solid tumours | Details |
PT-199 | PT-199 | Phase 1 Clinical | Phanes Therapeutics Inc | Colonic Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis; Lung Neoplasms; Thyroid Neoplasms; Colorectal Neoplasms; Breast Neoplasms; Pancreatic Neoplasms; Head and Neck Neoplasms; Triple Negative Breast Neoplasms; Neoplasms; Stomach Neoplasms; Esophageal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Ovarian Neoplasms; Solid tumours | Details |
INCA-00186 | INCA-00186 | Phase 1 Clinical | Incyte Corp Ltd | Solid tumours; Squamous Cell Carcinoma of Head and Neck; Neoplasms; Gastrointestinal Neoplasms | Details |
CB-708 | CB-708; CB708; ATG-037 | Phase 1 Clinical | Calithera Biosciences Inc | Solid tumours; Neoplasms | Details |
SRF-373(Surface Oncology) | SRF-373; NZV-930 | Phase 1 Clinical | Surface Oncology Inc | Ovarian Neoplasms; Solid tumours; Carcinoma, Renal Cell; Triple Negative Breast Neoplasms; Prostatic Neoplasms; Colorectal Neoplasms; Carcinoma, Pancreatic Ductal; Carcinoma, Non-Small-Cell Lung | Details |
HLX-23 | HLX-23 | Phase 1 Clinical | Shanghai Henlius Biologics Co Ltd | Solid tumours | Details |
Quemliclustat | AB-680 | Phase 2 Clinical | Arcus Biosciences Inc, Gilead Sciences Inc | Pancreatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Colorectal Neoplasms | Details |
Dalutrafusp alfa | AGEN-1423; GS-1423 | Phase 2 Clinical | Gilead Inc, Agenus Inc | Solid tumours; Pancreatic Neoplasms; Neoplasms; Carcinoma, Pancreatic Ductal | Details |
Oleclumab | MEDI-9447 | Phase 3 Clinical | Medimmune Llc | Solid tumours; Squamous Cell Carcinoma of Head and Neck; Carcinoma; Carcinoma, Renal Cell; Hemangiosarcoma; Triple Negative Breast Neoplasms; Neoplasms; Pancreatic Neoplasms; Urinary Bladder Neoplasms; Liposarcoma; Prostatic Neoplasms; Osteosarcoma; Colorectal Neoplasms; Carcinoma, Pancreatic Ductal; Carcinoma, Non-Small-Cell Lung | Details |
Dresbuxelimab | AK-119 | Phase 2 Clinical | Akeso Pharmaceuticals Inc | Solid tumours; Idiopathic Pulmonary Fibrosis; Coronavirus Disease 2019 (COVID-19); Carcinoma, Non-Small-Cell Lung | Details |
Uliledlimab | TJ-004309; TJD-5; TJ-4309 | Phase 2 Clinical | I-Mab Biopharma Co Ltd | Solid tumours; Ovarian Neoplasms; Head and Neck Neoplasms; Carcinoma, Ovarian Epithelial; Triple Negative Breast Neoplasms; Neoplasm Metastasis; Gastrointestinal Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
This web search service is supported by Google Inc.